Beta-氨基-Alpha-甲基-苯乙醇 | 52500-61-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: Beta-氨基-Alpha-甲基-苯乙醇
• 英文名称: isonorephedrine
• 英文别名: 1-amino-1-phenyl-2-propanol；2-hydroxy-1-phenylpropylamine；1-amino-1-phenylpropan-2-ol；1-Amino-2-hydroxy-1-phenyl-propan；β-amino-α-methylphenethyl alcohol；β-Oxy-α-phenyl-propylamin；Methyl-(α-amino-benzyl)-carbinol；1-phenyl-2-hydroxypropylamine
• CAS: 52500-61-5
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: AAEOXZIUGCXWTF-UHFFFAOYSA-N

物化性质

• 熔点：
  76-80℃
• 沸点：
  288℃
• 密度：
  1.071
• 闪点：
  128℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090
• 储存条件：
  存储条件：2-8°C，避光，惰性气体

反应信息

• 作为反应物：
  描述：

  Beta-氨基-Alpha-甲基-苯乙醇 在 草酰氯 、 potassium carbonate 、 二甲基亚砜 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.37h， 生成 N-[α-(Methylcarbonyl)benzyl]-2-phenylquinoline-4-carboxamide
  参考文献：
  名称：

  Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human Neurokinin-3 Receptor. 2. Identification of (S)-N-(1-Phenylpropyl)-3-hydroxy-2- phenylquinoline-4-carboxamide (SB 223412)

  摘要：

  Optimization of the previously reported 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonist 14, with regard to potential metabolic instability of the ester moiety and affinity and selectivity for the human neurokinin-3 (hNK-3) receptor, is described. The ester functionality could be successfully replaced by the ketone (31) or by lower alkyl groups (Et, 21, or n-Pr, 24). Investigation of the substitution pattern of the quinoline ring resulted in the identification of position 3 as a key position to enhance hNK-3 binding affinity and selectivity for the hNK-3 versus the hNK-2 receptor. All of the chemical groups introduced at this position, with the exception of halogens, increased the hNK-3 binding affinity, and compounds 53 (3-OH, SE 223412, hNK-3-CHO binding K-i = 1.4 nM) and 55 (3-NHz, hNK-3-CHO binding K-i = 1.2 nM) were the most potent compounds of this series. Selectivity studies versus the other neurokinin receptors (hNK-8-CHO and hNK-1-CHO) revealed that 53 is about 100-fold selective for the hNK-3 versus hNK-2 receptor, with no affinity for the hNK-1 at concentrations up to 100 mu M. In vitro studies demonstrated that 53 is a potent functional antagonist of the hNK-3 receptor (reversal of senktide-induced contractions in rabbit isolated iris sphincter muscles and reversal of NKB-induced Ca2+ mobilization in CHO cells stably expressing the hNK-3 receptor), while in vivo this compound showed oral and intravenous activity in NK-3 receptor-driven models (senktide-induced behavioral responses in mice and senktide-induced miosis in rabbits). Overall, the biological data indicate that (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (53, SE 223412) may serve as a pharmacological tool in animal models of disease to assess the functional and pathophysiological role of the NK-3 receptor and to establish therapeutic indications for non-peptide NK-3 receptor antagonists.

  DOI：

  10.1021/jm980633c
• 作为产物：
  描述：

  苯基丙酮 在 platinum(IV) oxide 亚硝酸特丁酯 、 氢气 、 sodium ethanolate 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 Beta-氨基-Alpha-甲基-苯乙醇
  参考文献：
  名称：

  2-氨基5-芳基-2-恶唑酮。强大的新型阳极代理商。

  摘要：

  DOI：

  10.1021/jm00339a011

文献信息

• PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME
  申请人：Mikoshiba Katsuhiko

  公开号：US20120277423A1

  公开（公告）日：2012-11-01

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R 1 is a substituted or unsubstituted aryl or heterocyclyl group, R 2 , R 3 , and R 4 are hydrogen atoms, n is 2, X is halogen, R 5 and R 6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R 5 and R 6 are not hydrogen atoms at the same time, or R 5 and R 6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及：一种具有转谷氨酰胺酶抑制活性的酮化合物，由下式1、2或3表示： 其中R1是取代或未取代的芳基或杂环基团，R2、R3和R4是氢原子，n是2，X是卤素，R5和R6独立地表示氢原子或取代或未取代的C1-C10烷基、芳基或芳烷基团，其中R5和R6不同时为氢原子，或者R5和R6可以共同形成含氮原子（N）的饱和或未饱和的、取代或未取代的杂环基团；包含该化合物的蛋白质交联抑制剂；以及包含该化合物或蛋白质交联抑制剂的用于预防或治疗由蛋白质交联引起的疾病的组合物。
• [EN] BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS BENZOLACTAMES UTILISÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2017068412A1

  公开（公告）日：2017-04-27

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof. The compounds are inhibitors of ERK 1/2 kinases and will be useful in the treatment of ERKl/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  该发明提供了一个化合物，其化学式为(0)：或其药学上可接受的盐、N-氧化物或互变异构体。这些化合物是ERK 1/2激酶的抑制剂，并将在治疗ERKl/2介导的疾病中发挥作用。因此，这些化合物在治疗中特别是在癌症治疗中是有用的。
• [EN] PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES<br/>[FR] DERIVES DE PYRAZOLE EN TANT QU'INHIBITEURS DE RECEPTEUR TYROSINE KINASES
  申请人：ASTRAZENECA AB

  公开号：WO2005049033A1

  公开（公告）日：2005-06-02

  Compounds of formula (I): and their use in the inhibition of Trk activity are described.

  化合物的化学式（I）及其在抑制Trk活性中的应用被描述。
• Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists
  申请人：SmithKline Beecham S.p.A.

  公开号：US20020068827A1

  公开（公告）日：2002-06-06

  A compound of formula (I): 1 or a salt thereof, or a solvate thereof, wherein, Ar is an optionally substituted aryl or a C 5-7 cycloalkdienyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C 1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C 1-6 alkyl, amino C 1-6 alkyl, C 1-6 alkylaminoalkyl, di C 1-6 alkylaminoalkyl, C 1-6 acylaminoalkyl, C 1-6 alkoxyalkyl, C 1-6 alkylcarbonyl, carboxy, C 1-6 alkoxycarbonyl, C 1-6 alkoxycarbonyl C 1-6 alkyl, aminocarbonyl, C 1-6 alkylaminocarbonyl, di C 1-6 alkylaminocarbonyl, halogeno C 1-6 alkyl; or R is a group —(CH 2 ) p — wherein p is 2 or 3 which group forms a ring with a carbon atom of Ar; R 1 represents hydrogen or up to four optional subtitutents selected from the list consisting of: C 1-6 alkyl, C 1-6 alkenyl, aryl, C 1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C 1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono- and di-C 1-6 alkylamino; R 2 represents hydrogen, C 1-6 -alkyl, hydroxy, halogen, cyano, amino, mono- or di-C 1-6 -alkylamino, alkylsulphonylamino, mono- or di-C 1-6 -alkanoylamino wherein any alkyl group is optionally substituted with an amino group or with a mono- or di-alkylamino group, or R 2 is a moiety —X—(CH 2 ) n —Y wherein X is a bond or —O— and n is an integer in the range of from 1 to 5 providing that when X is —O— n is only an integer from 2 to 5 and Y represents a group NY 1 Y 2 wherein Y 1 and Y 2 are independently selected from hydrogen, C 1-6 -alkyl, C 1-6 -alkenyl, aryl or aryl-C 1-6 -alkyl or Y is hydroxy, halogen or an optionally substituted N-linked single or fused ring, heterocyclic group, R 3 is branched or linear C 1-6 alkyl, C 3-7 cycloalkyl, C 4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R 4 represents hydrogen or C 1-6 alkyl; a process for the preparation of such a compound, a pharmaceutical compositon containing such a compound and the use of such a compound or composition in medicine.

  一个式为（I）的化合物： 或其盐，或其溶剂合物，其中，Ar是可选择取代的芳基或C 5-7 环烯烃基团，或可选择取代的单个或融合环芳香杂环基团； R是C 1-6 烷基，C 3-7 环烷基，C 3-7 环烷基烷基，可选择取代的苯基或苯基C 1-6 烷基，可选择取代的含有最多四个来自O和N的杂原子的五元杂芳环，羟基C 1-6 烷基，氨基C 1-6 烷基，C 1-6 烷基氨基烷基，二C 1-6 烷基氨基烷基，C 1-6 酰胺基烷基，C 1-6 烷氧基烷基，C 1-6 烷基羰基，羧基，C 1-6 烷氧羰基，C 1-6 烷氧羰基C 1-6 烷基，氨基羰基，C 1-6 烷基氨基羰基，二C 1-6 烷基氨基羰基，卤代C 1-6 烷基；或R是一个基团—(CH 2 ) p —其中p为2或3，该基团与Ar的一个碳原子形成环； R 1 代表氢或来自以下列表中选择的最多四个可选取代基：C 1-6 烷基，C 1-6 烯基，芳基，C 1-6 烷氧基，羟基，卤素，硝基，氰基，羧基，羧胺基，磺胺基，C 1-6 烷氧羰基，三氟甲基，酰氧基，邻苯二甲酰胺基，氨基或单-和双-C 1-6 烷基氨基； R 2 代表氢，C 1-6 -烷基，羟基，卤素，氰基，氨基，单-或双-C 1-6 -烷基氨基，烷基磺酰氨基，单-或双-C 1-6 -酰胺基，其中任何烷基基团可选择地取代为氨基基团或单-或双-烷基氨基基团，或R 2 是一个基团—X—(CH 2 ) n —Y，其中X是键或—O—，n是在1到5范围内的整数，要求当X为—O—时，n仅为2到5之间的整数，Y代表一个基团NY 1 Y 2 ，其中Y 1 和Y 2 分别选择自氢，C 1-6 -烷基，C 1-6 -烯基，芳基或芳基-C 1-6 -烷基，或Y为羟基，卤素或可选择取代的N-连接的单个或融合环杂环基团， R 3 是支链或直链C 1-6 烷基，C 3-7 环烷基，C 4-7 环烷基烷基，可选择取代的芳基，或可选择取代的单个或融合环芳香杂环基团；和 R 4 代表氢或C 1-6 烷基；一种制备这种化合物的方法，含有这种化合物的药物组合物以及这种化合物或组合物在医学中的用途。
• Quinoline derivatives(2)
  申请人：SmithKline Beecham Farmaceutici S.p.A.

  公开号：US05811553A1

  公开（公告）日：1998-09-22

  NK.sub.3 receptor antagonists of formula (I): ##STR1## are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.

  公式（I）的NK.sub.3受体拮抗剂：##STR1##对治疗包括肺部疾病、中枢神经系统疾病和神经退行性疾病等疾病很有用。